SYDNEY, AUSTRALIA: BCAL Diagnostics Limited, an Australian biotech company developing a blood test for breast cancer, has announced the appointment of Mr Shane Ryan as its Chief Operating Officer, effective from 21 September 2023.
Mr Ryan will oversee the clinical, marketing, and business development aspects of the company, as well as its global partnerships and compliance.
Mr Ryan has more than 20 years of experience in the global oncology market, especially in breast cancer. He has worked with GenesisCare, where he introduced the precision medicine test for Ductal Carcinoma In-situ (DCISionRT), and Peter MacCallum Cancer Centre, where he held executive positions in clinical operations, services development and surgery.
BCAL co-founder and executive chair Jayne Shaw said: “We are delighted to welcome Shane to the BCAL Executive team. He brings a depth of knowledge and experience to our organisation which will be invaluable as we move our BREASTESTIm to the market next year. He is widely known and respected as a trusted partner and collaborator in the Global breast cancer community.”
Mr Ryan will be responsible for fostering connections with global oncology key opinion leaders and breast surgeons. He will also be integral in developing the strategy for acquiring samples from prospective cancer patients, advancing the BCAL Biobank ready for commercialisation in 2024.
Leave a Reply